Homeoprotein Msx1-PIASy Interaction Inhibits Angiogenesis.
Animals
Chick Embryo
Human Umbilical Vein Endothelial Cells
Humans
MSX1 Transcription Factor
/ metabolism
Mice
Mice, Inbred BALB C
Neovascularization, Physiologic
Poly-ADP-Ribose Binding Proteins
/ metabolism
Protein Binding
Protein Inhibitors of Activated STAT
/ metabolism
Vascular Endothelial Growth Factor A
/ metabolism
Msx1
PIASy
VEGF
angiogenesis
protein stabilization
Journal
Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052
Informations de publication
Date de publication:
07 08 2020
07 08 2020
Historique:
received:
15
06
2020
revised:
17
07
2020
accepted:
03
08
2020
entrez:
14
8
2020
pubmed:
14
8
2020
medline:
24
3
2021
Statut:
epublish
Résumé
Previously, we demonstrated that the homeoprotein Msx1 interaction with p53 inhibited tumor growth by inducing apoptosis. However, Msx1 can exert its tumor suppressive effect through the inhibition of angiogenesis since growth of the tumor relies on sufficient blood supply from the existing vessels to provide oxygen and nutrients for tumor growth. We hypothesized that the inhibition of tumor growth by Msx1 might be due to the inhibition of angiogenesis. Here, we explored the role of Msx1 in angiogenesis. Overexpression of Msx1 in HUVECs inhibited angiogenesis, and silencing of Msx1 by siRNA abrogated its anti-angiogenic effects. Furthermore, forced expression of Msx1 in mouse muscle tissue inhibited vessel sprouting, and application of an Ad-Msx1-transfected conditioned medium onto the chicken chorioallantoic membrane (CAM) led to a significant inhibition of new vessel formation. To explore the underlying mechanism of Msx1-mediated angiogenesis, yeast two-hybrid screening was performed, and we identified PIASy (protein inhibitor of activated STAT Y) as a novel Msx1-interacting protein. We mapped the homeodomain of Msx1 and the C-terminal domain of PIASy as respective interacting domains. Consistent with its anti-angiogenic function, overexpression of Msx1 suppressed the reporter activity of VEGF. Interestingly, PIASy stabilized Msx1 protein, whereas deletion of the Msx1-interacting domain in PIASy abrogated the inhibition of tube formation and the stabilization of Msx1 protein. Our findings suggest the functional importance of PIASy-Msx1 interaction in Msx1-mediated angiogenesis inhibition.
Identifiants
pubmed: 32784646
pii: cells9081854
doi: 10.3390/cells9081854
pmc: PMC7463958
pii:
doi:
Substances chimiques
MSX1 Transcription Factor
0
MSX1 protein, human
0
PIAS4 protein, human
0
Poly-ADP-Ribose Binding Proteins
0
Protein Inhibitors of Activated STAT
0
VEGFA protein, human
0
Vascular Endothelial Growth Factor A
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
Int J Cancer. 2001 Aug 15;93(4):516-25
pubmed: 11477555
Mol Ther. 2004 Mar;9(3):464-74
pubmed: 15006615
Genes Dev. 2001 Dec 1;15(23):3088-103
pubmed: 11731474
Biochem Biophys Res Commun. 2015 Dec 4-11;468(1-2):326-30
pubmed: 26505791
Cancer Res. 2005 Jan 1;65(1):137-48
pubmed: 15665289
Genes Dev. 2006 Apr 1;20(7):784-94
pubmed: 16600910
CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96
pubmed: 18287387
Biol Open. 2012 Apr 15;1(4):376-84
pubmed: 23213427
Am J Pathol. 2002 Dec;161(6):2099-109
pubmed: 12466126
Nat Med. 2003 Jun;9(6):685-93
pubmed: 12778167
Biochem Biophys Res Commun. 2004 Jun 18;319(1):275-82
pubmed: 15158472
Proc Natl Acad Sci U S A. 1996 Sep 17;93(19):10128-33
pubmed: 8816763
J Cell Biol. 2000 Jan 24;148(2):343-51
pubmed: 10648567
Oncology (Williston Park). 2019 Jul 16;33(7):
pubmed: 31365748
Nat Med. 1997 May;3(5):505-9
pubmed: 9142117
Int J Cancer. 2010 Apr 15;126(8):1777-1787
pubmed: 19904748
Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4488-93
pubmed: 10200289
Oncogene. 2010 Oct 14;29(41):5568-78
pubmed: 20661221
Nature. 1994 Feb 10;367(6463):576-9
pubmed: 8107827
J Clin Diagn Res. 2015 Jun;9(6):XE01-XE05
pubmed: 26266204
Biochem J. 2007 Aug 1;405(3):481-8
pubmed: 17456046
Cell Mol Life Sci. 2003 Dec;60(12):2561-74
pubmed: 14685683
Cancer Res. 2005 Feb 1;65(3):749-57
pubmed: 15705871
Semin Oncol. 1997 Apr;24(2):203-18
pubmed: 9129690
Biochem Biophys Res Commun. 2009 Apr 3;381(2):241-6
pubmed: 19338779
Cancer Res. 2001 Sep 1;61(17):6532-9
pubmed: 11522651
Dev Dyn. 2008 Aug;237(8):2187-94
pubmed: 18627106
J Cell Biol. 1997 Oct 6;139(1):257-64
pubmed: 9314544
Dev Cell. 2009 Feb;16(2):167-79
pubmed: 19217420
Circ Res. 2003 Jun 13;92(11):1201-8
pubmed: 12750312
Angiogenesis. 2005;8(2):169-82
pubmed: 16211363
Nat Med. 2003 Jun;9(6):669-76
pubmed: 12778165
Biochem Biophys Res Commun. 2001 Mar;281(5):1234-40
pubmed: 11243867
J Am Soc Nephrol. 2019 Feb;30(2):187-200
pubmed: 30642877
Sci Rep. 2019 Oct 31;9(1):15771
pubmed: 31673071
Science. 2004 Jun 11;304(5677):1675-8
pubmed: 15192231
J Cell Biol. 2015 Sep 28;210(7):1239-56
pubmed: 26391659
Biochem Biophys Res Commun. 2006 Jul 14;345(4):1536-46
pubmed: 16729975
Nucleic Acids Res. 2005 Apr 28;33(8):e74
pubmed: 15860771
Nat Clin Pract Oncol. 2008 Apr;5(4):194-204
pubmed: 18268546
Proc Natl Acad Sci U S A. 2002 Mar 5;99(5):2872-7
pubmed: 11867732
Gene. 2000 Apr 18;247(1-2):17-31
pubmed: 10773441